Journal article
Comparison of the INNO-LiPA and PapType assays for detection of human papillomavirus in archival vulva dysplasia and/or neoplasia tissue biopsy specimens
SE Tan, SM Garland, AR Rumbold, SN Tabrizi
Journal of Clinical Microbiology | Published : 2011
DOI: 10.1128/JCM.00516-11
Abstract
INNO-LiPA and PapType human papillomavirus (HPV) genotyping assays were compared for detection of HPV genotypes on archival vulvar tissue. The INNO-LiPA assay detected 49 HPV-16 infections, compared with 47 detected by the PapType assay. The INNO-LiPA assay detected amplifiable DNA in 59 (91%) biopsy specimens, compared with 57 (88%) specimens for which amplifiable DNA was detected by the PapType assay. The two genotyping assays were highly comparable. Copyright © 2011, American Society for Microbiology. All Rights Reserved.
Grants
Funding Acknowledgements
[ "S.E.T. was supported by The Royal Women's Hospital Post Graduate Degree Scholarship from The Royal Women's Hospital and the Women's Centre for Infectious Diseases, The Royal Women's Hospital, Melbourne, Australia. A. R. R. is supported by the Jean B. Reid Fellowship from the University of Adelaide Medical Endowment Funds.", "S.M.G. and S.N.T. were previously members of the clinical development advisory board at Genera Biosystems; however, this advisory board has ceased to exist. S. M. G. has received advisory board fees and grant support from CSL Biotherapies and GlaxoSmithKline (GSK), lecture fees from Merck, GSK, and Sanofi Pasteur, and funding (through her employing institution) to conduct HPV vaccine studies for Merck, Sharp and Dohme (MSD) and GSK and is a member of the Merck Global Advisory Board and the Merck Scientific Advisory Committee for HPV. This relates to work outside this study. S. E. T. is the recipient of a GSK Australian Postgraduate Support Grant for work outside this study. CSL has provided funding to the authorship group to support a workshop on genetic susceptibility to vulvar cancer." ]